Ipsen

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:05:07 16/07/2024 pm IST			5-day change	1st Jan Change
110.8 ^EUR	-0.27%		+0.18%	+2.69%

11/07	CAC40: maintains gains after reassuring US inflation figures	CF
11/07	CAC40: rise without volume, W-Street at its zenith but falls back	CF

IPSEN : Buy back programme Art 5 of MAR Week 28 2024

July 16, 2024 at 09:34 pm IST

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

16 Jul 2024 18:00 CEST

Issuer

IPSEN

Aggregatedpresentationbydayandbymarket

Purchases of own shares from July 8th to 12th 2024

Name of the Issuer	Identity code of the Issuer	Day of the transaction	Identity code of the financial instrument	Total daily volume (in number of shares)	Daily weighted average purchase price of the shares	Market (MIC Code)
IPSEN	549300M6SGDPB4Z94P11	08/07/2024	FR0010259150	6 650	111,0282	XPAR
IPSEN	549300M6SGDPB4Z94P11	08/07/2024	FR0010259150	2 700	110,9397	CEUX
IPSEN	549300M6SGDPB4Z94P11	08/07/2024	FR0010259150	350	111,1231	TQEX
IPSEN	549300M6SGDPB4Z94P11	08/07/2024	FR0010259150	300	111,2180	AQEU
IPSEN	549300M6SGDPB4Z94P11	09/07/2024	FR0010259150	4 900	109,7478	XPAR
IPSEN	549300M6SGDPB4Z94P11	09/07/2024	FR0010259150	2 100	109,6744	CEUX
IPSEN	549300M6SGDPB4Z94P11	10/07/2024	FR0010259150	5 382	108,6341	XPAR
IPSEN	549300M6SGDPB4Z94P11	10/07/2024	FR0010259150	2 000	108,7151	CEUX
IPSEN	549300M6SGDPB4Z94P11	11/07/2024	FR0010259150	1 487	110,1258	XPAR
IPSEN	549300M6SGDPB4Z94P11	11/07/2024	FR0010259150	299	110,1107	CEUX
			TOTAL	26 168	109,9431

Attachment

EN_IPSEN - Buy-back programme - Art 5 of MAR - Week 28_2024

Source

Ipsen Pharma

Provider

GlobeNewswire

Company Name

IPSEN

ISIN

FR0010259150

Symbol

IPN

Market

Euronext

Attachments

Original Link
Permalink

Disclaimer

Ipsen SA published this content on 16 July 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 July 2024 16:03:05 UTC.

Latest news about Ipsen

CAC40: maintains gains after reassuring US inflation figures	11/07	CF
CAC40: rise without volume, W-Street at its zenith but falls back	11/07	CF
CAC40: over 7600pts before US inflation figures	11/07	CF
Ipsen: worldwide licensing agreement with Foreseen	11/07	CF
Ipsen, Foreseen Biotechnology Ink Exclusive Global Licensing Deal for Antibody-drug Conjugate	11/07	MT
Markets Powered by Alternating Current	10/07
Hutchmed Shares Rise After Tazemetostat Gets Priority Review Status in China	05/07	MT
Ipsen Expands Partnership with Exelixis for Cabometyx	02/07	MT
Ipsen extends collaboration with Exelixis	02/07	CF
IPSEN : UBS remains positive ahead of quarterly results	26/06	CF
Ipsen: share price soars, UBS confirms its recommendation	12/06	CF
IPSEN : UBS remains Buy after FDA approval	12/06	CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	11/06	CI
Ipsen: FDA grants approval for treatment	11/06	CF
Ipsen Secures US FDA's Accelerated Approval for Liver Disease Drug Iqirvo	11/06	MT
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment	11/06	MT
Ipsen's Rare Liver Disease Treatment Gets FDA OK	11/06	DJ
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	11/06	RE
US FDA approves Genfit and Ipsen's liver disease drug	11/06	RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics	07/06	MT
Ipsen: research partnership with Marengo extended	07/06	CF
Ipsen Hires New Chief Corporate Affairs Officer	06/06	MT
Ipsen: new Chief Corporate Affairs Officer	06/06	CF
Ipsen: new positive data in PBC	05/06	CF
Ipsen: mandate to an ISP for share buybacks	03/06	CF

Chart Ipsen

Duration

Period

More charts

Company Profile

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

24/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 08:20 pm IST

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

111.1 EUR

Average target price

127.3 EUR

Spread / Average Target

+14.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+2.69%	10.02B
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B

Other Pharmaceuticals

Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

IPSEN : Buy back programme Art 5 of MAR Week 28 2024

EPS Revisions